Masimo Corporation Shareholders: Ownership Structure, Brands, and Acquisition History
Last updated: Sep-2026Ownership Structure
Stakes approximate based on latest filings.
Ownership Analysis
For anyone evaluating this acquisition, the ownership picture is now unambiguous: Masimo sits entirely inside Danaher Corporation's corporate structure, with no minority public float, no independent board, and no separate shareholder base to answer to. That clean, complete transfer is worth underscoring because Masimo's path here was anything but linear. Just two years before the Danaher deal closed, the company was locked in a bruising proxy contest that stripped its founder of his board seat, and only a year before closing it was still working through the mechanics of divesting an entire consumer electronics division it had built through acquisition. We think the speed of the final transition, from a $350 million divestiture in 2025 to a $9.9 billion sale in 2026, says something about how quickly a company's strategic narrative can be rewritten once activist pressure forces management to simplify the business. Buyers considering how to read Masimo's trajectory should recognize that Danaher's ownership did not emerge from a slow, deliberate courtship; it followed directly on the heels of governance turmoil and a sharpened, healthcare-only profile that made Masimo a cleaner acquisition target. There is also a structural lesson here for anyone tracking how diversified conglomerates like Danaher build out their diagnostics and monitoring platforms: full ownership through an all-cash tender gives Danaher complete control over integration timing, cost synergies, and how much of Masimo's identity is preserved versus absorbed. Unlike a joint venture or minority stake, this structure leaves no ambiguity about who bears the execution risk of combining Masimo's patient monitoring technology with Danaher's existing diagnostics businesses. Anyone modeling out how this asset will perform under new ownership should treat Danaher's capital allocation priorities, not Masimo's historical public guidance, as the operative signal going forward, since the disclosure regime that once governed Masimo's independent reporting has now ended entirely.
Direct Owners
Institutional Shareholders
Shareholder Analysis
When we look at who benefited from this ownership change, the answer centers on two groups whose interests diverged sharply until the very end. Politan Capital Management, which built roughly a 6.2% stake and spent 2024 pushing for boardroom change, ultimately exited at the same $180.00 per share price available to every other shareholder, meaning its activist campaign and its final payday were resolved together rather than through a separate settlement. That outcome matters for anyone evaluating this acquisition because it shows the proxy fight functioned less as an isolated governance event and more as a catalyst that set the stage for the eventual sale, with the consumer audio divestiture and leadership change both preceding Danaher's approach. Founder Joe Kiani, who built Masimo from a startup into a multi-billion-dollar public company over nearly four decades, left before the final sale was even negotiated, meaning the person most identified with the company's origin story had no seat at the table when the acquisition terms were set. For institutional holders who stayed through the transaction, the $180.00 per share cash price represented a clean, immediate realization of value rather than an ongoing equity stake in the combined Danaher business, a distinction worth flagging for anyone assessing whether this was a growth-oriented merger or a straightforward buyout. We would also note that the absence of any remaining minority shareholders or disclosed institutional ownership figures reflects the totality of the transaction structure: this was not a partial stake sale or a staged buy-in, but a complete going-private transaction executed through a strategic acquirer. Readers trying to understand shareholder dynamics here should treat the Politan campaign as the inflection point that reshaped Masimo's board and leadership, and the Danaher deal as the mechanism that ultimately monetized those changes for everyone who held shares through closing.
Brands, Subsidiaries & Companies Owned
| Name | Type | Description |
|---|---|---|
| Signal Extraction Technology | Core Technology Platform | Masimo's founding pulse oximetry signal-processing platform designed to deliver accurate readings during patient motion and low perfusion |
| rainbow Pulse CO-Oximetry | Technology Platform | Multi-wavelength noninvasive monitoring platform measuring hemoglobin, oxygen content, and other blood constituents beyond standard oxygen saturation |
| Root Patient Monitoring and Connectivity Platform | Product Platform | Modular hospital bedside hub that integrates Masimo and third-party monitoring parameters into a single display |
| Radical-7 and Radical-97 Pulse Oximeters | Product Line | Bedside and handheld monitors used across hospital, emergency, and home care settings |
| SedLine Brain Function Monitoring | Product Line | Processed electroencephalography technology used to monitor anesthetic and sedation depth during surgery |
| O3 Regional Oximetry | Product Line | Noninvasive cerebral and regional tissue oxygen saturation monitoring used in cardiac and neonatal care |
| Patient SafetyNet | Software and Service | Remote patient surveillance monitoring system used to alert clinicians to patient deterioration on hospital wards |
| Masimo Hospital Automation | Software Platform | Clinical workflow and connected-care software suite built in part from the 2020 NantHealth connected care acquisition |
| Masimo W1 and Stork Consumer Health Devices | Consumer Health Product Line | Wearable health-tracking watch and infant monitoring products retained by Masimo after the Sound United divestiture |
Portfolio Analysis
Masimo's brand portfolio looked meaningfully different at the moment Danaher's acquisition closed than it did just a few years earlier, and that difference matters for anyone assessing what Danaher actually bought. Gone are the consumer audio names, Denon, Marantz, Polk Audio, Definitive Technology, and Bowers and Wilkins, all of which were sold to HARMAN International in 2025 and are no longer part of the Masimo umbrella. What remains, and what Danaher acquired, is a concentrated set of clinical technology platforms: Signal Extraction Technology pulse oximetry, the rainbow Pulse CO-Oximetry platform, the Root connectivity hub, Radical-series bedside and handheld monitors, SedLine brain function monitoring, O3 regional oximetry, and the Patient SafetyNet remote surveillance system. Each of these represents years of clinical validation and hospital installed-base relationships that are considerably harder to replicate than a consumer electronics label, which is precisely why we think Danaher's interest centered on the healthcare-only version of Masimo rather than the diversified company that existed in 2022 or 2023. Masimo also retained a smaller consumer health footprint, including the W1 wearable and Stork infant monitor, distinct from the audio brands it shed, suggesting the company drew a clear line between health-adjacent consumer products it wanted to keep and pure entertainment audio it did not. For anyone evaluating this transition, the brand story is really a story of strategic narrowing: a company that spent 2022 broadening its footprint into unrelated consumer categories spent 2025 and 2026 doing the opposite, shedding everything outside its clinical core before being folded into a diagnostics-focused parent. That sequencing suggests the Sound United divestiture was not incidental to the Danaher deal but a necessary precondition for it, since an acquirer built primarily on hospital diagnostics and life sciences would have had little strategic use for consumer loudspeaker brands.
Market Share & Competitors
Bubble size reflects relative market share.
| Company | Market Share | Revenue | Key Strength |
|---|---|---|---|
| Masimo Corporation ★ | N/A | $1.52B | Patient monitoring and hospital automation technology company that became a wholly owned subsidiary of Danaher Corporation following its 2026 acquisition |
| Medtronic plc | N/A | $36.36B | Diversified medical device maker competing with Masimo in patient monitoring, surgical, and cardiac technologies |
| GE HealthCare Technologies | N/A | $20.60B | Imaging and patient monitoring equipment provider that competes directly with Masimo in hospital bedside monitoring |
| Koninklijke Philips | N/A | $19.00B | Dutch health technology company offering patient monitoring and connected care solutions that compete with Masimo's hospital platforms |
| ResMed Inc | N/A | $5.15B | Sleep apnea and respiratory care device maker competing with Masimo in home and remote patient monitoring |
Competitive Analysis
Within the competitive landscape Masimo occupied before this deal, the company held a differentiated niche in noninvasive patient monitoring built on its Signal Extraction Technology, competing against considerably larger diversified medical device makers including Medtronic, GE HealthCare, Philips, and ResMed, each with a broader global reach. Each of these rivals brings a broader product footprint and materially greater revenue scale, Medtronic alone generates well over twenty times Masimo's healthcare revenue, yet Masimo carved out durable share in pulse oximetry and hospital connectivity through clinical accuracy claims and long-standing hospital relationships that proved resilient even during the company's governance turmoil. For anyone evaluating this acquisition, the competitive logic from Danaher's side is fairly direct: acquiring Masimo gives Danaher's Diagnostics segment a strong patient monitoring and hospital automation franchise to sit alongside existing units like Radiometer and Beckman Coulter Diagnostics, filling a gap Danaher did not previously address as thoroughly. We would also flag that Masimo's competitive position had been somewhat clouded by the Sound United detour and the leadership instability of 2024 and 2025, both of which risked distracting management and sales teams from core clinical accounts at exactly the moment competitors like GE HealthCare and Philips were investing heavily in connected monitoring platforms. Under Danaher's ownership, Masimo's technology gains access to a larger balance sheet and an operating system, the Danaher Business System, that has historically driven margin improvement and disciplined execution across its acquired businesses. For anyone assessing how the competitive landscape shifts from here, the relevant question is whether Danaher can stabilize and then accelerate Masimo's commercial execution faster than rivals can close the technology gap, particularly given that Masimo enters this new ownership structure with a narrower, more focused product portfolio than it had at any point in the prior five years.
Acquisitions
Bubble size reflects relative deal value.
| Company Acquired | Deal Value | Year | Description |
|---|---|---|---|
| NantHealth Connected Care Business | Undisclosed | 2020 | Masimo acquired NantHealth's connected care assets including remote patient surveillance and clinical workflow software, strengthening its hospital automation platform |
| TNI medical AG | Undisclosed | 2020 | Masimo acquired German noninvasive ventilation company TNI medical AG, adding respiratory therapy devices to its hospital product portfolio |
Acquisitions Analysis
Masimo's own acquisition history is modest compared with the scale of the deal that ultimately absorbed it, but it still offers useful context for anyone evaluating this transition. The company's two notable buys prior to Sound United, the 2020 purchase of NantHealth's connected care business and the same-year acquisition of German ventilation maker TNI medical AG, were both undisclosed in value and clearly aimed at deepening Masimo's hospital automation and respiratory therapy capabilities rather than diversifying its business model. That changed decisively in 2022 with the Sound United acquisition, a considerably larger and strategically riskier move into consumer audio that pulled Masimo away from its clinical focus and, as we noted elsewhere, became a lightning rod for activist criticism. We think the contrast between these two acquisition eras is instructive: the earlier, smaller deals reinforced what Masimo already did well, while the Sound United purchase represented a bet on synergies between medical wearables and consumer electronics that the market and Masimo's own shareholders ultimately rejected. The 2025 divestiture of Sound United to HARMAN International effectively reversed that bet, and the fact that Masimo itself became an acquisition target within roughly a year of completing that unwind suggests the market read the divestiture as Masimo preparing itself for sale rather than simply correcting course. For anyone tracking how this rounds out, Danaher's $9.9 billion purchase of Masimo dwarfs anything Masimo itself ever acquired, and it should be read less as a continuation of Masimo's own M&A pattern and more as the terminal event in a broader consolidation story, where a mid-cap medical device company's acquisitions of smaller technology assets ultimately gave way to its own absorption by a much larger diagnostics platform.
Acquisition Timeline
Merger & Spin-off History
Merger & Spin-off Analysis
The merger and divestiture history here compresses an unusual amount of corporate change into a short window, and anyone evaluating this transition should treat that compression as a signal rather than noise. Masimo's 2022 acquisition of Sound United was a genuine strategic pivot, an attempt to build a broader consumer technology company alongside its medical device core, and it is worth remembering that the deal was defended by management at the time as a way to expand retail channels and engineering resources. That rationale did not hold up under activist scrutiny, and by 2025 Masimo had reversed course entirely, selling Sound United to HARMAN International for $350 million, a fraction of what it likely paid to assemble the audio portfolio in the first place. We think that gap between acquisition cost and divestiture proceeds is itself a meaningful data point for anyone assessing how much value the Sound United detour destroyed, even though the exact original purchase price was not consistently disclosed. What followed the divestiture was not a return to steady-state independence but a rapid move toward the company's own sale, with Danaher's offer arriving within roughly nine months of the Sound United transaction closing. For anyone evaluating how these events fit together, the sequence reads as a single connected narrative: an activist investor identified capital allocation problems, forced a leadership and strategic reset, and the resulting simplified, healthcare-focused company became an attractive acquisition target almost immediately thereafter. That is a meaningfully different story than a gradual, opportunistic sale process, and it suggests the Danaher transaction should be understood as the direct output of the governance fight rather than a separate, unrelated event in Masimo's corporate history.
Ownership History
Ownership History Analysis
Masimo's ownership history traces an arc from founder-led independence to full absorption into a much larger parent, and the milestones along that path are unusually well documented for anyone evaluating this transition. Joe Kiani founded the company in 1989 and led it through its 2007 initial public offering, building Masimo into a respected name in pulse oximetry over roughly three and a half decades of founder control. That era ended abruptly in 2024 and 2025: Politan Capital Management's proxy campaign cost Kiani his board seat in September 2024, and he resigned as chief executive shortly after, a remarkably fast fall for a company's namesake founder. We think the speed of that leadership transition, from board loss to full CEO departure in a matter of days, reflects how thoroughly the activist campaign had undermined Kiani's standing with the broader shareholder base by that point. Michelle Brennan's appointment as interim leadership and the subsequent search for permanent executive leadership marked Masimo's first sustained period without Kiani at the helm since its founding. The company then moved quickly to reshape its business, divesting Sound United in 2025 and agreeing to be acquired by Danaher in early 2026, closing that sale by mid-2026. For anyone tracking how ownership transitions unfold in practice, Masimo's case offers a clear example of how activist pressure, leadership change, portfolio simplification, and an eventual sale can follow one another in rapid succession once a board loses confidence in existing strategy. The company that Danaher ultimately acquired was, in nearly every structural respect, a different entity than the one Politan targeted in 2024, having shed both its founder and its consumer audio ambitions before finally losing its independence altogether.
Ownership Explained
Masimo Corporation, the Irvine, California-based patient monitoring technology company founded by Joe Kiani in 1989, operates today as a wholly owned subsidiary of Danaher Corporation, a diversified life sciences and diagnostics conglomerate listed on the New York Stock Exchange under the ticker DHR. Danaher announced a definitive agreement to acquire Masimo on February 17, 2026, for $180.00 per share in an all-cash transaction valued at roughly $9.9 billion, and the deal closed on June 10, 2026, after receiving shareholder and regulatory approval. Masimo shares, which had traded on Nasdaq under the ticker MASI, were delisted upon closing. The acquisition followed a turbulent two-year stretch for Masimo, including a 2024 proxy fight with activist investor Politan Capital Management that cost founder Joe Kiani his board seat and, in 2025, his role as chief executive, as well as the 2025 divestiture of the Sound United consumer audio business to HARMAN International, a Samsung subsidiary, which returned Masimo to a healthcare-only focus shortly before the Danaher deal was struck. Within Danaher, Masimo now operates as a standalone business inside the Diagnostics segment alongside units such as Radiometer, Cepheid, Leica Biosystems, and Beckman Coulter Diagnostics.
Ownership by Danaher Corporation means Masimo no longer has its own publicly traded shares, its own board of directors, or independent shareholder votes; strategic and capital allocation decisions are now made by Danaher's management and board as part of the parent company's broader Diagnostics segment portfolio. Masimo's former shareholders, including activist investor Politan Capital Management, received cash at $180.00 per share when the deal closed and no longer hold an equity interest in the business. Day-to-day, Masimo is expected to continue operating under its own brand and product lines, similar to how Danaher has historically run acquired diagnostics businesses as standalone operating companies within its Danaher Business System framework, but ultimate financial reporting, executive oversight, and long-term strategy now flow through Danaher's corporate structure rather than an independent public filing regime.